IN PARTNERSHIP WITH CSI -...
Transcript of IN PARTNERSHIP WITH CSI -...
IN PARTNERSHIP WITH CSI
FIRST ANNOUNCEMENT
Apr.14-16, 2017
Hangzhou, China
SPONSORSecond A�liated Hospital, Zhejiang University School of Medicine
CO-SPONSORCSI (Catheter Interventions in Congenital, Structural and Valvular Heart Disease)
WELCOMING REMARKS
Dear colleagues and friends,
Incidence of valvular heart diseases keeps increasing along with the
aging trend of the world, and makes it a serious threat to human health.
As the evidence accumulates, transcatheter valvular replacement or
repair emerged as an alternative for traditional cardiac surgery,
especially in the �eld of transcatheter aortic valve replacement (TAVR).
However, development of transcatheter valvular treatment in China is
still at the initial status. There is an urgent call for systemic training for
Chinese interventional cardiologists and their heart valve teams.
To improve transcatheter valvular treatment in China and international
collaboration in the �eld, the third China Valve (Hangzhou) congress
will be held on 14th to 16th April 2017. This year, we will continuously
work with the support of CSI to provide a broader global vision, an
improved training course and a deeper communicative platform. The
program will include step by step learning from recorded cases, live
cases, hands-on sessions, imaging training, up-to-date clinical trials
and debates on hot spots, etc.
Hangzhou is an ancient, yet highly civilized city rich in both historical
sites and natural landscapes, such as the West Lake and Grand Canal.
The city is also an international metropolis where the G20 summit held
in September 2016. You will have the opportunity to enjoy the wonder-
ful scenery after scienti�c activities.
Welcome to Hangzhou!
Course Chairman: Junbo Ge
Course Directors: Jian’an Wang Horst Sievert
ORGANIZATION
Honorable Chairmen
Course Chairman
Course Directors
Runlin GAO
(Beijing, China)
Yong HUO
(Beijing, China)
Junbo GE
(Shanghai, China)
Jian’an WANG
(Zhejiang, China)
Horst SIEVERT
(Course director of CSI, Germany)
ORGANIZATION
International Faculties (In Alphabetic Order)
Anthony DEMARIA (UCSD Medical Center, USA)
Khalil FATTOUCH (Maria Eleonora Hospital, Italy)
Ulrich GERCKENS (Gemeinschaftskrankenhaus, Bonn, Germany)
Robert GOOLEY (MonashHEART, Australia) Eberhard GRUBE (Siegburg Heart Center, Germany)
Kentaro HAYASHIDA (Keio University, Japan) Dongming HOU (USA)
Hasan JILAIHAWI (NYU Langone Medical Center, USA)
Patrizio LANCELLOTTI (University of Liège, Belgium)
Thomas MODINE (Lille University Hospital, France)
Duk-Woo PARK (ASAN Medical Center,Korea)
Advisory Committee (In Alphabetic Order)
Daniel Tai-Leung CHAN (Queen Mary Hospital, Hong Kong) Mao CHEN (Sichuan, China)
Yundai CHEN (Beijing, China) Yaling HAN (Shenyang, China)
Dejia HUANG (Sichuan, China) Xiangqing KONG (Jiangsu, China)
Michael Kang-yin LEE (Queen Elizabeth Hospital, Hongkong) Simon Cheung-Chi LAM (Queen Mary Hospital, Hong Kong)
Yat-Yin LAM(Hongkong Society of Congenital and Structural Heart Disease) Yongjian WU (Beijing, China)
Bo XU (Beijing, China) Yuejing YANG (Beijing, China)
Wei-Hsian YIN (Cheng-Hsin General Hospital, Taiwan) Ruiyan ZHANG (Shanghai, China)
Daxin ZHOU (Shanghai, China)
Scienti�c Committee (In Alphabetic Order)
Jiyan CHEN (Guangdong, China) Shaoliang CHEN (Jiangsu, China)
Xiaoshu CHEN (Jiangxi, China) Yuan FENG (Sichuan, China)
Yingqiang GUO (Sichuan,China) Ben HE (Shanghai, China) Guoqing LI (Xinjiang, China) Xianhe LIN (Anhui, China) Genshan MA (Jiangsu, China) Yitong MA (Xinjiang, China) Yongwen QIN(Shanghai, China) Xi SU (Hubei, China) Yong SUN (Zhejiang, China) Ling TAO (Shanxi, China) Hongju WANG (Anhui, China) Yan WANG (Fujian, China) Qiang WU (Guizhou, China) Yanqing WU (Jiangxi, China) Meixiang XIANG (Zhejiang, China) Biao XU (Jiangsu, China) Bo YU (Heilongjiang, China) Zaixin YU (Hunan, China) Zuyi YUAN (Shanxi, China) Heng ZHANG (Anhui, China) Xianxian ZHAO (Shanghai, China)
Secretariats
Jun JIANG (Zhejiang, China) Xianbao LIU (Zhejiang, China)
PROGRAM DRAFT
April 14 Friday
Main ArenaSession 1: 13:30-15:00 Learning from recorded TAVR case step by step
Clinical evaluation
Echocardiographic evaluation
CT analysis
Heart valve team discussion
(cardiologist, surgeon, anesthesiologist, radiologist, nurse etc.)
Recorded TAVR case step by step
Session 2: 15:30-16:30 Optimising TAVR outcomes
Clinical situation: where are the limits
How to evaluate and get vascular access safely
How to choose correct THV and valve size
Double S curve guided deployment
Session 3: 17:00-18:00 Making TAVR simple?
Local or general anesthesia?
TTE or TEE guidance?
Hybrid or ordinary catheter room?
Will TAVR be performed as PCI in the future?
Heart valve team will be changed in the future?
Room 3
Hands on training
How to perform transcatheter self-expanding aortic valve with VENUS A
How to perform transcatheter mechanical-expanding Lotus valve
April 15 Saturday
Main ArenaSession 4 08:00-09:00 Moving farward to lower risk patients
What’s the real di�erence between high risk and lower risk patients
The limitations of surgery in lower risk patient-perspectives from interventionalist
The limitations of TAVR in lower risk patient-perspectives from surgeon
Latest evidence and limitations
PROGRAM DRAFT
April 15 Saturday
Main Arena09:00-09:30 Opening ceremony
Session 5 09:30-10:30 Dialogues of TAVR between China and the world
Current status
Bicuspid aortic valve
Severe calci�cation and thickened lea�ets
Home-made devices and new generation devices
Perspectives from cardiologists and surgeons
Session 6 10:30-12:30 Live cases
Session 7 13:30-15:00 Long term outcomes and bioprothetic valve durability
Controversies of TAVR bioprostheses deterioration
Why might TAVR bioprotheses fail
Lessons from surgical experience
Subclinical thrombosis and lea�et thickening
TAV in TAV: current status and future
TAVR for younger patients: my thinking
Session 8 15:00-17:00 Live cases
Session 9 17:00-18:00 Percutaneous mitral and tricuspid valves intervention
Anatomic challenges
Update of transcatheter mitral valve replacement or repair
Current status of percutaneous tricuspid valve intervention
Experience from China
Room 2
Session1 13:30-15:30 TAVR for bicuspid aortic valve
Anatomic characteristics and procedural considerations
What guideline say and up-to-date outcomes of clinical studies
Advantages and disadvantages of di�erent transcatheter heart valves
Sizing strategy and outcomes - experience from China
Cases
Session2 16:00-18:00 International challenging TAVR cases
PROGRAM DRAFT
Room 3 Hands on training
How to perform transcatheter self-expanding aortic valve with VENUS A
How to perform transcatheter mechanical-expanding Lotus valve
April 16 Sunday
Main ArenaSession 10 08:00-09:00 How to design TAVR clinical studies and get published
Session 11 09:00-10:30 Management of complications-1
Case 1 PVL
How to prevent and treat PVL
Case 2 vascular complication
How to prevent and treat vascular complications
Case 3 conduction disturbance
Predictors of conduction disturbance and how to minimize PPM
Session 12 10:30-12:00 Management of complications-2
Case 4 stroke
Predictors of stroke and prevention
Case 5 Coronary obstruction
How to prevent and treat coronary obstructions
Case 6 annulus rupture or myocardial perforation
How to prevent and treat annulus rupture or myocardial perforation
Room 3
Hands on training
How to perform transcatheter self-expanding aortic valve with VENUS A
How to perform transcatheter mechanical-expanding Lotus valve
CONFERENCE INFORMATION
Conference Venue The Dragon Hotel, Hangzhou, China
Address 120 Shuguang Road, Hangzhou, China 310007
Hotel Tel +86 400 600 0676
Website www.china-valve.org.cn
Pre-registration on line up to 31st March, 2017
Pre-registration Fee ¥800
Registration on the spot 14th to 15th April, 2017
Registration Fee ¥1000
Contacts Qiyuan Xu Yan Lin
Tel +86 158 6904 9557 +86 187 6811 5530
Email CVH2017@ china-valve.org.cn